Deal Snapshot
PORTAGE AWAITS CSE REVIEW, SHAREHOLDER VOTE FOR ACQUISITION OF SALVARX
Thursday 11 October 2018

Canadian biotechnology company Portage Biotech Inc (CSE: PBT.U) (OTC: PTGEF) continues to await final work toward obtaining shareholder approvals for its acquisition of 100% of immuno-oncology specialist SalvaRx Ltd from SalvaRx Group plc, the company said.
Canadian securities exchange CSE is continuing to review Portage's filing. Portage will issue a further news release when shareholder meeting materials have been approved for distribution and a trade resumption date set.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 11/10/2018
Target: SalvaRx Ltd
Country: Canada
Deal Size: 71.70m (USD)
Sector: Biotechnology
Type: Corporate acquisition
Financing: Stock
Status: Agreed
Vendor: SalvaRx Group, James Mellon,  and Gregory Bailey 
Buyer: Hitachi Data Systems Corp
Comment:


Options